SCHEMBL3972943

SCHEMBL3972943

CC(C)(C)OC(=O)NCC1(c2ccc([N+](=O)[O-])cc2)CCCCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
CYP2C19 P33261 3/20 0.40
MEN1 O00255 2/20 0.40
CYP1A2 P05177 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
THRB P10828 2/20 0.39
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTR1E P28566 1/20 0.38
S1PR3 Q99500 1/20 0.38
TP53 P04637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HTT P42858 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
ADRB2 P07550 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3967950 0.80 HTT (0.50) LMNAMAPTALDH1A1HTTTDP1
SCHEMBL15713061 0.72 THRB (0.45) LMNACYP2C19CYP1A2KMT2ACYP2D6
SCHEMBL17109514 0.72 MAPT (0.43) LMNACYP2C19MEN1CYP1A2KMT2A
SCHEMBL4093183 0.71 MAPT (0.45) LMNACYP2C19MEN1CYP1A2KMT2A
SCHEMBL18347567 0.70 MAPT (0.54) LMNACYP2C19MEN1CYP1A2KMT2A
SCHEMBL3904346 0.70 MEN1 (0.58) LMNACYP2C19MEN1CYP1A2KMT2A
SCHEMBL5366689 0.69 CYP2C19 (0.44) LMNACYP2C19MEN1CYP1A2KMT2A
SCHEMBL372131 0.69 PPARG (0.51) CYP2C19MAPTALDH1A1PPARGPPARA
SCHEMBL18542634 0.69 MGLL (0.50) LMNACYP1A2KMT2ACYP3A4MAPT
SCHEMBL23728041 0.67 PPARG (0.49) LMNAMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
EP-2016070-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES LMNA 3217/4885CYP2C19 2319/4885MEN1 740/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES LMNA 3217/4885CYP2C19 2319/4885MEN1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.